UNLABELLED: The multiple-drug resistance (MDR) transporter P-glycoprotein (P-gp) is highly expressed at the human blood-brain barrier (BBB). P-gp actively effluxes a wide variety of drugs from the central nervous system, including anticancer drugs. We have previously demonstrated P-gp activity at the human BBB using PET of (11)C-verapamil distribution into the brain in the absence and presence of the P-gp inhibitor cyclosporine-A (CsA). Here we extend the initial noncompartmental analysis of these data and apply compartmental modeling to these human verapamil imaging studies. METHODS: Healthy volunteers were injected with (15)O-water to assess blood flow, followed by (11)C-verapamil to assess BBB P-gp activity. Arterial blood samples and PET images were obtained at frequent intervals for 5 and 45 min, respectively, after injection. After a 60-min infusion of CsA (intravenously, 2.5 mg/kg/h) to inhibit P-gp, a second set of water and verapamil PET studies was conducted, followed by (11)C-CO imaging to measure regional blood volume. Blood flow was estimated using dynamic (15)O-water data and a flow-dispersion model. Dynamic (11)C-verapamil data were assessed by a 2-tissue-compartment (2C) model of delivery and retention and a 1-tissue-compartment model using the first 10 min of data (1C(10)). RESULTS: The 2C model was able to fit the full dataset both before and during P-pg inhibition. CsA modulation of P-gp increased blood-brain transfer (K(1)) of verapamil into the brain by 73% (range, 30%-118%; n = 12). This increase was significantly greater than changes in blood flow (13%; range, 12%-49%; n = 12, P < 0.001). Estimates of K(1) from the 1C(10) model correlated to estimates from the 2C model (r = 0.99, n = 12), indicating that a short study could effectively estimate P-gp activity. CONCLUSION: (11)C-verapamil and compartmental analysis can estimate P-gp activity at the BBB by imaging before and during P-gp inhibition by CsA, indicated by a change in verapamil transport (K(1)). Inhibition of P-gp unmasks verapamil trapping in brain tissue that requires a 2C model for long imaging times; however, transport can be effectively measured using a short scan time with a 1C(10) model, avoiding complications with labeled metabolites and tracer retention.
UNLABELLED: The multiple-drug resistance (MDR) transporter P-glycoprotein (P-gp) is highly expressed at the human blood-brain barrier (BBB). P-gp actively effluxes a wide variety of drugs from the central nervous system, including anticancer drugs. We have previously demonstrated P-gp activity at the human BBB using PET of (11)C-verapamil distribution into the brain in the absence and presence of the P-gp inhibitor cyclosporine-A (CsA). Here we extend the initial noncompartmental analysis of these data and apply compartmental modeling to these human verapamil imaging studies. METHODS: Healthy volunteers were injected with (15)O-water to assess blood flow, followed by (11)C-verapamil to assess BBB P-gp activity. Arterial blood samples and PET images were obtained at frequent intervals for 5 and 45 min, respectively, after injection. After a 60-min infusion of CsA (intravenously, 2.5 mg/kg/h) to inhibit P-gp, a second set of water and verapamil PET studies was conducted, followed by (11)C-CO imaging to measure regional blood volume. Blood flow was estimated using dynamic (15)O-water data and a flow-dispersion model. Dynamic (11)C-verapamil data were assessed by a 2-tissue-compartment (2C) model of delivery and retention and a 1-tissue-compartment model using the first 10 min of data (1C(10)). RESULTS: The 2C model was able to fit the full dataset both before and during P-pg inhibition. CsA modulation of P-gp increased blood-brain transfer (K(1)) of verapamil into the brain by 73% (range, 30%-118%; n = 12). This increase was significantly greater than changes in blood flow (13%; range, 12%-49%; n = 12, P < 0.001). Estimates of K(1) from the 1C(10) model correlated to estimates from the 2C model (r = 0.99, n = 12), indicating that a short study could effectively estimate P-gp activity. CONCLUSION: (11)C-verapamil and compartmental analysis can estimate P-gp activity at the BBB by imaging before and during P-gp inhibition by CsA, indicated by a change in verapamil transport (K(1)). Inhibition of P-gp unmasks verapamil trapping in brain tissue that requires a 2C model for long imaging times; however, transport can be effectively measured using a short scan time with a 1C(10) model, avoiding complications with labeled metabolites and tracer retention.
Authors: Mark Lubberink; Gert Luurtsema; Bart N M van Berckel; Ronald Boellaard; Rolf Toornvliet; Albert D Windhorst; Eric J F Franssen; Adriaan A Lammertsma Journal: J Cereb Blood Flow Metab Date: 2006-06-07 Impact factor: 6.200
Authors: Mark Muzi; Alexander M Spence; Finbarr O'Sullivan; David A Mankoff; Joanne M Wells; John R Grierson; Jeanne M Link; Kenneth A Krohn Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057
Authors: N H Hendrikse; E G de Vries; E J Franssen; W Vaalburg; W T van der Graaf Journal: Eur J Clin Pharmacol Date: 2001 Jan-Feb Impact factor: 2.953
Authors: Joost Bart; Antoon T M Willemsen; Harry J M Groen; Winette T A van der Graaf; Theodora D Wegman; Willem Vaalburg; Elisabeth G E de Vries; N Harry Hendrikse Journal: Neuroimage Date: 2003-11 Impact factor: 6.556
Authors: Aiman Abrahim; Gert Luurtsema; Martin Bauer; Rudolf Karch; Mark Lubberink; Ekaterina Pataraia; Christian Joukhadar; Kurt Kletter; Adriaan A Lammertsma; Christoph Baumgartner; Markus Müller; Oliver Langer Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-11 Impact factor: 9.236
Authors: Finbarr O'Sullivan; Mark Muzi; David A Mankoff; Janet F Eary; Alexander M Spence; Kenneth A Krohn Journal: Ann Appl Stat Date: 2014-06-01 Impact factor: 2.083
Authors: M Bauer; M Zeitlinger; R Karch; P Matzneller; J Stanek; W Jäger; M Böhmdorfer; W Wadsak; M Mitterhauser; J P Bankstahl; W Löscher; M Koepp; C Kuntner; M Müller; Oliver Langer Journal: Clin Pharmacol Ther Date: 2011-12-14 Impact factor: 6.875
Authors: Heli Savolainen; Albert D Windhorst; Philip H Elsinga; Mariangela Cantore; Nicola A Colabufo; Antoon Tm Willemsen; Gert Luurtsema Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: Viktoria Zoufal; Thomas Wanek; Markus Krohn; Severin Mairinger; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Pekar; Martin Bauer; Jens Pahnke; Oliver Langer Journal: J Cereb Blood Flow Metab Date: 2018-10-24 Impact factor: 6.200